Russian COVID-19 vaccine offers 92% efficacy against symptomatic COVID-19, interim analysis of phase 3 trial shows

Sub-analysis of 2,000 adults older than 60 years suggests the vaccine is similarly effective and well tolerated in this group.

Join OnMedica and benefit from:

  • Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
  • High-quality, evidence-based content developed by expert editors and clinicians
  • Articles, quizzes, videos, visual summaries and more
  • Regulatory alerts and round-up of medical journals
  • New content added daily, so you know you’re always up to date

Existing members Sign in